All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, March 5, 2021
Home » Blogs » BioWorld Perspectives » What’s 10 minus Four? Not Six, Apparently

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld / Vaccines

What’s 10 minus Four? Not Six, Apparently

Nov. 30, 2012
By Anette Breindl
No Comments

Dec. 1 is World AIDS Day, and when I reflect on AIDS, I generally do it with a sense of amazement about how far we have come in the treatment of HIV since AIDS first came to the attention of the U.S. medical establishment, in form of a cluster of pneumocystis pneumonia infections in young men, in 1981. An AIDS-free generation is no longer a pipe dream.

With all the progress that’s being made, though, I’ve been struck how one thing that seems to keep receding into the distance – like a manifestation of the joke that the future is always coming but never here – is a vaccine.

In February 2008, David Baltimore, said at the annual meeting of the American Association for the Advancement of Science that a vaccine has been at least 10 years away for the past 20 years.

Fast-forward to the July 2012 International AIDS conference, where Gary Nabel, director of the Vaccine Research Institute at the National Institute of Allergies and Infectious Disease, said that vaccines are “at least 10 years away under the best of circumstances.”

The reason this seems so striking to me is that I’ve written about AIDS vaccines for a number of years now, and there were significant advances in the time period between those two statements. In 2008, Baltimore characterized the AIDS vaccine situation as "there is no AIDS vaccine and no hopeful candidate vaccine."

Just a year later, the RV144 or Thai trial became the first clinical trial to demonstrate efficacy of an HIV vaccine, though the risk reduction was too modest to make the vaccine an option for widespread immunization campaigns.

Since then, dozens of broadly neutralizing antibodies have been identified that might form the basis of a vaccine. Researchers have gained new insights into how the B cell and T cell arms of the immune system each contribute to immunity in experimental HIV vaccines. And in one preclinical trial, about 50 percent of monkeys were protected against contracting SIV, and some appeared to be able to clear the infection, after vaccination with a viral vector-delivered vaccine.

So, dear readers: use the comments and give us your opinion. When will we be five years, instead of 10 years, away from an HIV vaccine? (“In five years” wins smart-aleck points but otherwise does not count.) And what will it take?

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 4.
  • Gloved hand places sample tubes in PCR system

    COVID-19 test makers are adapting for variants

    BioWorld MedTech
    As COVID-19 variants have emerged, so have questions about the effectiveness of tests for infection. While the risk of mutations significantly limiting their...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for March 4.
  • Celltrion-Regkirona-2-9

    Celltrion wins first conditional Korean approval for COVID-19 antibody Regkirona

    BioWorld
    HONG KONG – Celltrion Inc. has received conditional marketing authorization from the Ministry of Food and Drug Safety (MFDS) for its anti-COVID-19 monoclonal...
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing